Imatinib Mesylate: Past Successes and Future Challenges in the Treatment of Gastrointestinal Stromal Tumors
Just over a decade ago, gastrointestinal tumours were a poorly understood mesenchymal neoplasm unsuccessfully treated with chemotherapy. Cytotoxic therapy for advanced disease yielded response rates of 10% and median survival of just 18 months. However, the discovery of KIT and platelet derived grow...
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2011-01-01
|
Series: | Clinical Medicine Insights: Oncology |
Online Access: | https://doi.org/10.4137/CMO.S4259 |
_version_ | 1811333427787464704 |
---|---|
author | Doran Ksienski |
author_facet | Doran Ksienski |
author_sort | Doran Ksienski |
collection | DOAJ |
description | Just over a decade ago, gastrointestinal tumours were a poorly understood mesenchymal neoplasm unsuccessfully treated with chemotherapy. Cytotoxic therapy for advanced disease yielded response rates of 10% and median survival of just 18 months. However, the discovery of KIT and platelet derived growth factor receptor alpha ( PDGFRA ) mutations as oncogenic drivers of most gastrointestinal tumours, paved the way for targeted therapy. Imatinib mesylate, a tyrosine kinase inhibitor, produces a clinical benefit rate (complete response, partial response, and stable disease) of more than 80% in metastatic setting and a median survival of 57 months. Imatinib is now also approved in adult patients following resection of KIT-positive GIST. Major insights into the mechanism of action of imatinib, unique pharmacokinetics, drug resistance, and management of low grade but chronic adverse effects continue to be made. |
first_indexed | 2024-04-13T16:51:37Z |
format | Article |
id | doaj.art-f6efa0f2ada04b719ff134fc2feb7171 |
institution | Directory Open Access Journal |
issn | 1179-5549 |
language | English |
last_indexed | 2024-04-13T16:51:37Z |
publishDate | 2011-01-01 |
publisher | SAGE Publishing |
record_format | Article |
series | Clinical Medicine Insights: Oncology |
spelling | doaj.art-f6efa0f2ada04b719ff134fc2feb71712022-12-22T02:38:55ZengSAGE PublishingClinical Medicine Insights: Oncology1179-55492011-01-01510.4137/CMO.S4259Imatinib Mesylate: Past Successes and Future Challenges in the Treatment of Gastrointestinal Stromal TumorsDoran Ksienski0Victoria Island Cancer Center, Victoria, British Columbia, Canada, 2410 Lee Avenue V8R 6V5.Just over a decade ago, gastrointestinal tumours were a poorly understood mesenchymal neoplasm unsuccessfully treated with chemotherapy. Cytotoxic therapy for advanced disease yielded response rates of 10% and median survival of just 18 months. However, the discovery of KIT and platelet derived growth factor receptor alpha ( PDGFRA ) mutations as oncogenic drivers of most gastrointestinal tumours, paved the way for targeted therapy. Imatinib mesylate, a tyrosine kinase inhibitor, produces a clinical benefit rate (complete response, partial response, and stable disease) of more than 80% in metastatic setting and a median survival of 57 months. Imatinib is now also approved in adult patients following resection of KIT-positive GIST. Major insights into the mechanism of action of imatinib, unique pharmacokinetics, drug resistance, and management of low grade but chronic adverse effects continue to be made.https://doi.org/10.4137/CMO.S4259 |
spellingShingle | Doran Ksienski Imatinib Mesylate: Past Successes and Future Challenges in the Treatment of Gastrointestinal Stromal Tumors Clinical Medicine Insights: Oncology |
title | Imatinib Mesylate: Past Successes and Future Challenges in the Treatment of Gastrointestinal Stromal Tumors |
title_full | Imatinib Mesylate: Past Successes and Future Challenges in the Treatment of Gastrointestinal Stromal Tumors |
title_fullStr | Imatinib Mesylate: Past Successes and Future Challenges in the Treatment of Gastrointestinal Stromal Tumors |
title_full_unstemmed | Imatinib Mesylate: Past Successes and Future Challenges in the Treatment of Gastrointestinal Stromal Tumors |
title_short | Imatinib Mesylate: Past Successes and Future Challenges in the Treatment of Gastrointestinal Stromal Tumors |
title_sort | imatinib mesylate past successes and future challenges in the treatment of gastrointestinal stromal tumors |
url | https://doi.org/10.4137/CMO.S4259 |
work_keys_str_mv | AT doranksienski imatinibmesylatepastsuccessesandfuturechallengesinthetreatmentofgastrointestinalstromaltumors |